Incyte Announces European Commission Approval of Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma Life Science Investing
STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value Life Science Investing
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment Life Science Investing
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial Life Science Investing
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy Medical Device Investing
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer Life Science Investing
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D Life Science Investing
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference Life Science Investing
PADCEV Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Pharmaceutical Investing
